Resource Summary Report

Generated by RRID on Jul 29, 2026

B6CBA-Tg(HDexon1)62Gpb/1J

RRID:IMSR_JAX:002810
Type: Organism

Proper Citation

RRID:IMSR_JAX:002810

Organism Information

URL: https://www.jax.org/strain/002810

Proper Citation: RRID:IMSR_JAX:002810

Description: Mus musculus with name B6CBA-Tg(HDexon1)62Gpb/1J from IMSR.

Species: Mus musculus

Synonyms: B6CBA-TgN(HDexon1)62Gpb. B6CBA-Tg(HDexon1)62oGpb/J

Notes: gene symbol note: huntingtin|transgene insertion 62; Gillian Bates; mutant strain: HTT|Tg(HDexon1)62Gpb

Affected Gene: huntingtin|transgene insertion 62; Gillian Bates

Genomic Alteration: transgene insertion 62; Gillian Bates

Catalog Number: JAX:002810

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: B6CBA-Tg(HDexon1)62Gpb/1J

Record Creation Time: 20250513T053635+0000

Record Last Update: 20260725T044344+0000

Ratings and Alerts

No rating or validation information has been found for B6CBA-Tg(HDexon1)62Gpb/1J.

No alerts have been found for B6CBA-Tg(HDexon1)62Gpb/1J.

Data and Source Information

Source: Integrated Animals

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 317 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Oberländer K, et al. (2025) Inhba, Homer1 and Bdnf are major targets of transcriptomic dysregulation by neurodegenerative disease-associated excitotoxic NMDA receptor signaling. Communications biology, 8(1), 1743.

Frosch M, et al. (2025) Microglia-neuron crosstalk through Hex-GM2-MGL2 maintains brain homeostasis. Nature, 646(8086), 913.

Pradhan S, et al. (2025) Huntingtin preserves mitochondrial genome integrity in neurons, which is impaired in Huntington's disease. bioRxiv : the preprint server for biology.

Tung YS, et al. (2025) Insulin-like growth factor 2 reduces Huntington's disease aggregates via AKT and NF-?B signaling in huntington's disease. Cell & bioscience, 15(1), 109.

Bosica M, et al. (2025) Coiled-Coil Structures Mediate the Intercellular Propagation of Huntingtin. International journal of molecular sciences, 26(17).

Cheng CY, et al. (2025) The therapeutic potential of (R)-carvedilol in Huntington's disease through enhancement of autophagy-lysosomal pathway via GSK-3? inhibition. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 22(3), e00557.

Rusmini P, et al. (2025) Impairment of lysosomal quality control in Huntington disease. Cell death & disease, 16(1), 762.

Ikefuama EC, et al. (2025) Presymptomatic targeted circuit manipulation for ameliorating Huntington's disease pathogenesis. iScience, 28(3), 112022.

Kang YK, et al. (2025) Emergence of CpG-cluster blanket methylation in aged tissues: a novel signature of epigenomic aging. Nucleic acids research, 53(9).

Rubio C, et al. (2025) Animal Models for the Study of Neurological Diseases and Their Link to Sleep. Biomedicines, 13(8).

Sapp E, et al. (2025) Mutant huntingtin exon 1 protein detected in mouse brain with neoepitope antibody: effects of CAG repeat expansion, MutS Homolog 3 silencing and aggregation. Brain communications, 7(5), fcaf314.

Jiménez-Jiménez FJ, et al. (2025) Oxidative Stress in Huntington's Disease. Biomolecules, 15(4).

Kachemov M, et al. (2025) Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum. Brain : a journal of neurology, 148(4), 1212.

Simmons DA, et al. (2025) Human striatal progenitor cells that contain inducible safeguards and overexpress BDNF rescue Huntington's disease phenotypes. Molecular therapy. Methods & clinical development, 33(1), 101415.

Gao R, et al. (2025) Decoding Microglial Polarization and Metabolic Reprogramming in Neurodegenerative Diseases: Implications for Disease Progression and Therapy. Aging and disease, 17(1), 91.

Simmons DA, et al. (2025) Small molecule modulation of p75NTR engages the autophagy-lysosomal pathway and reduces huntingtin aggregates in cellular and mouse models of Huntington's disease. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 22(2), e00495.

Tung CW, et al. (2025) Exploring Cordycepin as a Neuroprotective Agent in Huntington's Disease: In Vitro and In Vivo Insights. Pharmacology research & perspectives, 13(2), e70091.

Fernández G, et al. (2025) Restoring endogenous Dlg4/PSD95 expression by an artificial transcription factor ameliorates cognitive and motor learning deficits in the R6/2 mouse model of Huntington's disease. Clinical epigenetics, 17(1), 100.

Everix L, et al. (2025) Assessment of changes in synaptic density in the zQ175DN mouse model of Huntington's disease: a [18F]SynVesT-1 study. NeuroImage. Clinical, 46, 103800.

König J, et al. (2025) Examination of Anti-Inflammatory Effects After Propionate Supplementation in the R6/2 Mouse Model of Huntington's Disease. International journal of molecular sciences, 26(7).